Health Tech Capitol | Propeller Health Raises Strategic Investment from McKesson Ventures
16295
post-template-default,single,single-post,postid-16295,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Propeller Health Raises Strategic Investment from McKesson Ventures

Propeller Health Raises Strategic Investment from McKesson Ventures

MADISON, Wis.June 11, 2018 /PRNewswire/ — Propeller Health, a leading digital therapeutics company, announced a strategic investment of an undisclosed amount from McKesson Ventures, adding to the $20M funding round announced last week.

Proceeds from the investment will provide further support for Propeller’s development of additional connected medicines for the treatment of chronic respiratory disease, such as injectables for severe asthma, and expansion into new therapeutic areas, which may include immunology, diabetes, migraine and other diseases with high unmet medical need.

“We’ve accumulated the expertise, infrastructure and distribution network to put connected medicines in the hands of people around the world,” said David Van Sickle, co-founder and CEO of Propeller Health. “This strategic investment accelerates those efforts and provides opportunities to explore potential partnership models that can increase access to new digital medicines and positively impact more lives.”

Read more at PR Newswire

No Comments

Sorry, the comment form is closed at this time.